MedTrace Logo

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

NCT01590069 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-21

No results posted yet for this study

Summary

This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs. Biological therapies, such as aerosolized aldesleukin, may stimulate or suppress the immune system in different ways and stop tumor cells from growing.

Conditions

  • Metastatic Malignant Neoplasm in the Lung
  • Metastatic Melanoma
  • Metastatic Osteosarcoma
  • Metastatic Renal Cell Cancer
  • Sarcoma
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Stage IV Osteosarcoma AJCC v7
  • Stage IV Renal Cell Cancer AJCC v7

Interventions

BIOLOGICAL

Aerosolized Aldesleukin

Breathe aerosolized aldesleukin

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Najat Daw · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-28
Primary Completion
2029-04-30
Completion
2029-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01590069 on ClinicalTrials.gov